Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology
- Pablo Valderrabano1⇑,
- Laila Khazai2,
- Marino E Leon2,†,
- Zachary J Thompson3,
- Zhenjun Ma3,
- Christine H Chung1,
- Julie E Hallanger-Johnson1,
- Kristen J Otto1,
- Kara D Rogers1,
- Barbara A Centeno2 and
- Bryan McIver1
- 1Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
- 2Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
- 3Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
- Correspondence should be addressed to P Valderrabano; Email: pablo.valderrabano{at}moffitt.org
-
Figure 1
ThyroSeq v2 performance results. ITN indicates indeterminate thyroid nodules; B-III, atypia/follicular lesion of undetermined significance; B-IV, follicular/Hürthle cell neoplasm; Sn, sensitivity; Sp, specificity; NPV, negative predictive value; and PPV, positive predictive value. Test metrics were calculated on resected nodules only with exact binomial 95% confidence intervals in 2 different scenarios: NIFTP considered ‘malignant’ (A) and NIFTP considered ‘benign’ (B).
- © 2017 Society for Endocrinology
